Latest Ratios: P/E Ratio -111.6x · EV/EBITDA N/A · ROE -6.0%. (1999–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $7.3B | $4.3B | $4.1B | $4.2B | $4.9B | $9.1B | $5.7B | $5.1B | $3.5B | $3.8B | $2.8B |
| Enterprise Value | $6.9B | $4.0B | $3.9B | $4.0B | $4.9B | $8.5B | $6.0B | $5.3B | $3.6B | $3.9B | $2.7B |
| P/E Ratio → | -111.55 | — | — | — | 53.41 | 4.32 | 454.79 | 263.59 | 41.48 | 81.01 | 44.83 |
| P/S Ratio | 9.28 | 5.50 | 7.04 | 5.38 | 4.77 | 12.69 | 11.06 | 10.84 | 4.00 | 4.98 | 3.95 |
| P/B Ratio | 6.60 | 3.94 | 3.81 | 3.48 | 3.48 | 4.13 | 4.71 | 4.61 | 3.25 | 4.01 | 3.33 |
| P/FCF | 110.73 | 65.62 | — | — | 107.99 | — | 48.03 | 34.19 | 23.28 | 21.58 | 23.35 |
| P/OCF | 76.11 | 45.10 | — | — | 68.10 | — | 41.63 | 30.85 | 20.00 | 20.19 | 21.37 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.04 | 6.59 | 5.17 | 4.82 | 11.82 | 11.76 | 11.14 | 4.18 | 5.07 | 3.85 |
| EV / EBITDA | — | — | — | 150.19 | 28.08 | 286.81 | — | — | 26.08 | 30.74 | 25.15 |
| EV / EBIT | — | — | — | — | 37.08 | — | — | — | 39.51 | 41.99 | 40.19 |
| EV / FCF | — | 60.08 | — | — | 109.04 | — | 51.10 | 35.13 | 24.34 | 21.99 | 22.76 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 58.2% | 58.2% | 53.4% | 58.9% | 62.7% | 59.0% | 57.7% | 59.1% | 60.1% | 59.1% | 60.4% |
| Operating Margin | -9.0% | -9.0% | -28.3% | -3.1% | 11.6% | -4.6% | -21.0% | -18.7% | 9.8% | 11.1% | 9.5% |
| Net Profit Margin | -8.3% | -8.3% | -32.7% | -4.4% | 8.9% | 293.7% | 2.5% | 4.1% | 9.6% | 6.1% | 8.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -6.0% | -6.0% | -16.7% | -2.6% | 5.1% | 124.1% | 1.1% | 1.8% | 8.3% | 5.3% | 7.7% |
| ROA | -5.2% | -5.2% | -14.3% | -1.9% | 3.6% | 85.5% | 0.7% | 1.2% | 5.3% | 3.6% | 5.9% |
| ROIC | -6.8% | -6.8% | -13.3% | -1.5% | 5.9% | -1.6% | -5.7% | -5.4% | 5.7% | 7.1% | 6.7% |
| ROCE | -6.3% | -6.3% | -13.8% | -1.5% | 5.6% | -1.6% | -6.6% | -5.9% | 6.0% | 7.3% | 7.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.02 | 0.05 | 0.39 | 0.20 | 0.47 | 0.33 | 0.33 | 0.36 | 0.09 |
| Debt / EBITDA | — | — | — | 2.41 | 3.11 | 15.16 | — | — | 2.55 | 2.70 | 0.68 |
| Net Debt / Equity | — | -0.33 | -0.24 | -0.13 | 0.03 | -0.28 | 0.30 | 0.13 | 0.15 | 0.08 | -0.08 |
| Net Debt / EBITDA | — | — | — | -6.04 | 0.27 | -21.00 | — | — | 1.13 | 0.57 | -0.64 |
| Debt / FCF | — | -5.54 | — | — | 1.05 | — | 3.07 | 0.94 | 1.06 | 0.41 | -0.58 |
| Interest Coverage | -58.40 | -58.40 | -117.18 | -0.90 | 19.81 | -0.87 | -2.87 | -3.75 | 4.66 | 6.57 | 25.83 |
Net cash position: cash ($364M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.69 | 4.69 | 6.15 | 4.51 | 7.87 | 3.35 | 3.43 | 6.85 | 5.71 | 5.84 | 3.51 |
| Quick Ratio | 4.02 | 4.02 | 5.07 | 3.32 | 7.33 | 3.27 | 3.26 | 6.32 | 5.19 | 5.39 | 3.09 |
| Cash Ratio | 3.09 | 3.09 | 3.90 | 2.69 | 6.42 | 3.05 | 2.55 | 5.27 | 4.24 | 4.71 | 2.11 |
| Asset Turnover | — | 0.62 | 0.48 | 0.54 | 0.47 | 0.24 | 0.26 | 0.28 | 0.53 | 0.50 | 0.64 |
| Inventory Turnover | 3.43 | 3.43 | 2.58 | 1.66 | 3.80 | 5.99 | 4.51 | 2.65 | 4.63 | 4.30 | 4.63 |
| Days Sales Outstanding | — | 30.01 | 34.03 | 13.67 | 25.46 | 49.78 | 67.99 | 58.27 | 30.77 | 33.88 | 38.93 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 1.9% | 23.1% | 0.2% | 0.4% | 2.4% | 1.2% | 2.2% |
| FCF Yield | 0.9% | 1.5% | — | — | 0.9% | — | 2.1% | 2.9% | 4.3% | 4.6% | 4.3% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 5.2% | 18.1% | 12.6% | 0.3% | 0.5% | 1.1% | 0.0% | 1.5% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 5.2% | 18.1% | 12.6% | 0.3% | 0.5% | 1.1% | 0.0% | 1.5% |
| Shares Outstanding | — | $33M | $32M | $32M | $36M | $44M | $44M | $44M | $44M | $43M | $42M |
Includes 30+ ratios · 27 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SLAB stock.
Silicon Laboratories Inc.'s current P/E ratio is -111.6x. The historical average is 48.2x.
Silicon Laboratories Inc.'s return on equity (ROE) is -6.0%. The historical average is 12.3%.
Based on historical data, Silicon Laboratories Inc. is trading at a P/E of -111.6x. Compare with industry peers and growth rates for a complete picture.
Silicon Laboratories Inc. has 58.2% gross margin and -9.0% operating margin.
Key Metrics
Top Statement Risk
Operating losses despite revenue growth
Metrics are mathematically derived from official filings.
Margin Recovery Still Far from Breakeven
Gross margin expanded 980 basis points to 61.6% by 2026Q2, yet operating margin remains negative at -4.7%, indicating fixed costs still outpace revenue scaling, per reported quarterly data.
The gross margin improvement from 51.8% in 2024Q1 to 61.6% in 2026Q2 suggests strong pricing power and favorable product mix in the IoT portfolio, but the operating margin of -4.7% reveals that R&D and SG&A expenses, which remain elevated at roughly 40% of revenue, have not yet been absorbed by the growing top line. This implies that while the company is on a recovery trajectory, the path to sustainable profitability depends on continued revenue growth to achieve operating leverage, and investors should monitor whether the gross margin expansion can persist as competition in Matter-compatible chips intensifies.
Capital Returns Still Deeply Negative
ROIC improved from -4.4% in 2024Q1 to -1.1% in 2026Q2, but remains negative, indicating the company is still destroying value on invested capital, based on reported figures.
The steady improvement in ROIC from -4.4% to -1.1% over eight quarters reflects the cyclical recovery, yet the persistently negative returns suggest that the capital base, which includes $376.4 million in goodwill from prior acquisitions, is not yet generating sufficient operating income to cover its cost. This implies that management's high-conviction bet on the IoT-only strategy has not yet proven value-accretive, and the company must achieve positive operating margins to reverse the value destruction trend.
Working Capital Cycle Compresses Sharply
Cash conversion cycle fell from 281 days in 2024Q1 to 93 days in 2026Q2, driven by a 226-day reduction in days inventory outstanding, per quarterly financial data.
The dramatic compression in DIO from 344 days to 118 days indicates that the company has successfully cleared excess channel inventory from the semiconductor downturn, which is a positive sign for cash generation. However, the CCC remains elevated at 93 days compared to typical fabless peers, and the recent increase in DSO from 26 to 31 days suggests that the company may be extending payment terms to customers to drive growth, which could pressure future cash flows if the trend continues.
Debt-Free Balance Sheet Provides Flexibility
Silicon Laboratories carries no debt with a D/E ratio of zero, and interest coverage is not applicable, providing ample financial flexibility despite operating losses, as reported in the latest balance sheet.
The absence of debt on the balance sheet is a significant strength, as it means the company is not exposed to refinancing risk or covenant constraints, even as it continues to post operating losses. This financial flexibility allows management to sustain elevated R&D spending during the recovery phase without the pressure of debt service, but investors should note that the negative interest coverage ratios in the data are a function of net interest income rather than debt, and the company's cash position of $362.2 million provides a buffer against prolonged losses.
Liquidity Buffer Remains Fortress-Like
Current ratio stands at 5.41 with quick ratio at 4.41 as of 2026Q2, indicating a strong liquidity position that can withstand severe demand shocks, according to reported figures.
The current ratio has remained consistently above 4.5 over the past ten quarters, reflecting a conservative balance sheet with minimal reliance on short-term financing. This liquidity cushion is particularly important given the volatility in free cash flow, which swung from -$73.8 million in 2024Q1 to $43.3 million in 2025Q1 and back to -$26.8 million in 2026Q2, suggesting that the company can absorb working capital swings without distress.
EV/EBITDA Misleads on IoT Pure-Play
The forward EV/EBITDA of 413.99 is meaningless for a company with negative EBITDA, obscuring the true valuation signal; P/S of 9.22 better captures the growth premium, per current multiples.
Analysts commonly apply EV/EBITDA to semiconductor companies, but for Silicon Laboratories, which has negative EBITDA in the TTM period, this multiple is distorted and provides no useful comparison to profitable peers like Skyworks or Qorvo. Instead, investors should focus on EV/Sales or forward P/E, which at 76.83 implies the market is pricing in a significant earnings recovery that has not yet materialized, and the 9.22 P/S ratio suggests a premium valuation that may be justified only if the company achieves the operating leverage implied by its revenue growth trajectory.